NYSE$OGN
Organon & Co. · Q1 2026 earnings
Q1 2026 earnings · · Before market open · Investor relations
Briefing
OGN reported Q1 2026 revenue of $1.5B and net income of $146.0M, with diluted EPS of $0.55.
For Q1 2026, OGN reported revenue of $1.5B and net income of $146.0M. The quarterly 10-Q discusses segment performance, liquidity, and outlook in MD&A.
- Revenue of $1.5B for Q1 2026.
- Net income of $146.0M; diluted EPS $0.55.
- Operating trends and segment mix are detailed in the quarterly report.
- Liquidity, capital allocation, and macro exposure discussed in MD&A.
Headline financials
Revenue & EPS history
Organon · Revenue · Quarterly
$1.46B
Revenue by segment
Organon · $1.52B total across 4 segments · Q3 2023
- Established Brands$959M—63.1%
- Women's Health$376M—24.8%
- Biosimilars$144M—9.5%
- Other$40M—2.6%
Forward guidance
The filing discusses OGN's operating environment, capital priorities, and risks without issuing formal quarterly EPS guidance.
Tailwinds
- Management provides segment and liquidity detail in MD&A.
- Filing supports transparency on year-over-year trends.
Headwinds
- Macro, competitive, or regulatory risks noted in risk factors.
- No numeric full-year EPS bridge in the quarterly filing.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2026
-0.9%
Avg return
Earnings day
-1.6%
Avg return
5 days after
-4.8%
Avg return
30 days after
40%
10 / 25 earnings
Positive
+14.4%
Q4 2023
Best reaction
-26.9%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.6% | +0.1% | +0.1% | |
| Q4 2025 | -8.2% | -5.3% | -17.4% | |
| Q3 2025 | +14.0% | +11.1% | +5.9% | |
| Q1 2025 | -26.9% | -29.4% | -28.7% | |
| Q4 2024 | +11.0% | +5.3% | +4.1% | |
| Q3 2024 | +0.8% | -8.2% | -11.5% | |
| Q2 2024 | -5.6% | -0.2% | +5.8% | |
| Q1 2024 | +4.1% | +8.3% | +13.3% | |
| Q4 2023 | +14.4% | +13.0% | +11.7% | |
| Q3 2023 | -9.2% | -15.3% | -21.5% | |
| Q2 2023 | +6.2% | +6.2% | -10.7% | |
| Q1 2023 | -7.1% | -12.4% | -18.5% | |
| Q4 2022 | -11.1% | -7.6% | -25.9% | |
| Q3 2022 | -6.1% | -9.1% | +3.0% | |
| Q2 2022 | -3.3% | -3.6% | -12.5% | |
| Q1 2022 | +4.8% | +4.7% | +12.0% | |
| Q4 2019 | +0.8% | -0.3% | -4.9% | |
| Q4 2021 | -0.7% | -1.0% | -3.5% | |
| Q3 2020 | -3.9% | -5.1% | -17.2% | |
| Q3 2021 | -8.0% | -8.4% | -21.5% | |
| Q2 2020 | +3.4% | -2.9% | -1.4% | |
| Q2 2021 | +14.3% | +18.2% | +13.2% | |
| Q4 2020 | -1.5% | +0.7% | +1.6% | |
| Q1 2020 | -1.5% | +0.7% | +1.6% | |
| Q1 2021 | -1.5% | +0.7% | +1.6% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro